S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

$14.75
+0.03 (+0.20%)
(As of 03/27/2024 ET)
Today's Range
$14.72
$14.80
50-Day Range
$13.06
$15.00
52-Week Range
$11.53
$15.89
Volume
95,075 shs
Average Volume
99,768 shs
Market Capitalization
$214.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Merrimack Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
5.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Merrimack Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$11,441 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.10 out of 5 stars

Medical Sector

830th out of 939 stocks

Pharmaceutical Preparations Industry

384th out of 435 stocks

MACK stock logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

MACK Stock Price History

MACK Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Merrimack Reports Full Year 2023 Financial Results
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
MACK Mar 2024 14.000 put
MACK Mar 2024 4.000 put
MACK Feb 2024 16.000 put
Ipsen drug approved by FDA for early pancreatic cancer
Merrimack Pharmaceuticals Inc MACK
Merrimack Reports Third Quarter 2023 Financial Results
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
2000

Profitability

Net Income
$-1,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.31 per share

Miscellaneous

Free Float
10,337,000
Market Cap
$214.32 million
Optionable
Optionable
Beta
1.44

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

MACK Stock Analysis - Frequently Asked Questions

How have MACK shares performed in 2024?

Merrimack Pharmaceuticals' stock was trading at $13.41 on January 1st, 2024. Since then, MACK shares have increased by 10.0% and is now trading at $14.75.
View the best growth stocks for 2024 here
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter.

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.25%), Vanguard Group Inc. (4.19%), ADAR1 Capital Management LLC (3.84%), Dimensional Fund Advisors LP (3.04%), Northern Trust Corp (0.82%) and Barclays PLC (0.10%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends
.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MACK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners